^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | magrolimab (GS-4721) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Published date:
03/08/2023
Excerpt:
Median time to response, duration of CR, duration of overall response, and progression-free survival were 1.9, 11.1, 9.8, and 11.6 months, respectively…. In TP53-mutant patients, 40% achieved CR with median OS of 16.3 months....Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations.
Secondary therapy:
azacitidine
DOI:
10.1200/JCO.22.01794
Trial ID:
Source:
Title:
Tolerability and Effi cacy of the First-In- Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results
Published date:
09/21/2022
Excerpt:
Median durations of CR and CR/CRi were 7.7 (95% CI, 4.7-10.9) and 8.7 (95% CI, 5.3-10.9) months, respectively. Median overall survival was 10.8 months (95% CI, 6.8-12.8; 8.3-month median follow-up). : Magrolimab+azacitidine showed durable responses and encouraging overall survival in frontline patients with TP53-mutated AML unsuitable for intensive chemotherapy.
Trial ID:
Source:
Title:
Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
Published date:
09/21/2022
Excerpt:
Magrolimab+azacitidine was well tolerated, with promising effi cacy in patients with untreated HR MDS, including those with TP53-mutated and –wild-type disease.
Secondary therapy:
azacitidine
Trial ID:
